Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK1 | P28482 | 1/20 | 0.65 |
| ▸ | MEN1 | O00255 | 1/20 | 0.55 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.55 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.55 |
| ▸ | THRB | P10828 | 1/20 | 0.55 |
| ▸ | LGALS3 | P17931 | 2/20 | 0.53 |
| ▸ | LGALS8 | O00214 | 1/20 | 0.53 |
| ▸ | LGALS4 | P56470 | 1/20 | 0.53 |
| ▸ | CA1 | P00915 | 2/20 | 0.47 |
| ▸ | CA2 | P00918 | 2/20 | 0.47 |
| ▸ | CA9 | Q16790 | 2/20 | 0.47 |
| ▸ | CD69 | Q07108 | 1/20 | 0.47 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.47 |
| ▸ | B4GALT1 | P15291 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19935097 | 1.00 | MAPK1 (0.65) | MAPK1MEN1KMT2AALDH1A1THRB | |
| SCHEMBL2292636 | 1.00 | MAPK1 (0.65) | MAPK1MEN1KMT2AALDH1A1THRB | |
| SCHEMBL15260475 | 1.00 | MAPK1 (0.65) | MAPK1MEN1KMT2AALDH1A1THRB | |
| SCHEMBL730739 | 1.00 | MAPK1 (0.65) | MAPK1MEN1KMT2AALDH1A1THRB | |
| SCHEMBL24531188 | 1.00 | MAPK1 (0.65) | MAPK1MEN1KMT2AALDH1A1THRB | |
| SCHEMBL13671169 | 1.00 | MAPK1 (0.65) | MAPK1MEN1KMT2AALDH1A1THRB | |
| SCHEMBL23618308 | 1.00 | MAPK1 (0.65) | MAPK1MEN1KMT2AALDH1A1THRB | |
| SCHEMBL23133631 | 1.00 | MAPK1 (0.65) | MAPK1MEN1KMT2AALDH1A1THRB | |
| SCHEMBL24822648 | 1.00 | MAPK1 (0.65) | MAPK1MEN1KMT2AALDH1A1THRB | |
| SCHEMBL10261426 | 1.00 | MAPK1 (0.65) | MAPK1MEN1KMT2AALDH1A1THRB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2023107896-A9 | TREATMENT OF FGG RELATED DISEASES AND DISORDERS | EMPIRICO INC. (US) | 2024-07-11 | — | — | WO | disclosed |
| WO-2024137663-A2 | TREATMENT OF DKK2 RELATED DISEASES AND DISORDERS | EMPIRICO INC. (US) | 2024-06-27 | — | — | WO | disclosed |
| WO-2024129886-A2 | TREATMENT OF MST1 RELATED DISEASES AND DISORDERS | EMPIRICO INC. (US) | 2024-06-20 | — | — | WO | disclosed |
| WO-2024118979-A1 | TREATMENT OF MTRES1 RELATED DISEASES AND DISORDERS | EMPIRICO INC. (US) | 2024-06-06 | — | — | WO | disclosed |
| US-20240018523-A1 | GALNAC COMPOSITIONS FOR IMPROVING SIRNA BIOAVAILABILITY | EMPIRICO INC. | 2024-01-18 | — | — | US | disclosed |
| WO-2023250327-A1 | TREATMENT OF GPAM RELATED DISEASES AND DISORDERS | EMPIRICO INC. (US) | 2023-12-28 | — | — | WO | disclosed |
| WO-2023230478-A2 | TREATMENT OF SOS2 RELATED DISEASES AND DISORDERS | EMPIRICO INC. (US) | 2023-11-30 | — | — | WO | disclosed |
| WO-2023178264-A2 | TREATMENT OF HGFAC RELATED DISEASES AND DISORDERS | EMPIRICO INC. (US) | 2023-09-21 | — | — | WO | disclosed |
| WO-2023178144-A2 | GALNAC COMPOSITIONS FOR IMPROVING SIRNA BIOAVAILABILITY | EMPIRICO INC. (US) | 2023-09-21 | — | — | WO | disclosed |
| US-20230295630-A1 | GALNAC COMPOSITIONS FOR IMPROVING SIRNA BIOAVAILABILITY | EMPIRICO INC. | 2023-09-21 | — | — | US | disclosed |
| WO-2022271552-A1 | TREATMENT OF DKK2 RELATED DISEASES AND DISORDERS | EMPIRICO INC. (US) | 2022-12-29 | — | — | WO | disclosed |
| WO-2022266042-A1 | TREATMENT OF MST1R RELATED DISEASES AND DISORDERS | EMPIRICO INC. (US) | 2022-12-22 | — | — | WO | disclosed |
| WO-2022266037-A1 | TREATMENT OF MST1 RELATED DISEASES AND DISORDERS | EMPIRICO INC. (US) | 2022-12-22 | — | — | WO | disclosed |
| WO-2022266132-A1 | TREATMENT OF PLIN1 RELATED DISEASES AND DISORDERS | EMPIRICO INC. (US) | 2022-12-22 | — | — | WO | disclosed |
| WO-2022266045-A1 | TREATMENT OF MTRES1 RELATED DISEASES AND DISORDERS | EMPIRICO INC. (US) | 2022-12-22 | — | — | WO | disclosed |
| WO-2022261005-A1 | TREATMENT OF ANGPTL4 RELATED DISEASES | EMPIRICO INC. (US) | 2022-12-15 | — | — | WO | disclosed |
| WO-2022140365-A1 | GALNAC COMPOSITIONS FOR IMPROVING SIRNA BIOAVAILABILITY | EMPIRICO INC. (US) | 2022-06-30 | — | — | WO | disclosed |
| US-8987377-B2 | Poly(amide) polymers for the delivery of oligonucleotides | ALNYLAM PHARMACEUTICALS, INC. (US) | 2015-03-24 | — | — | US | disclosed |
| US-20130253135-A1 | POLY(AMIDE) POLYMERS FOR THE DELIVERY OF OLIGONUCLEOTIDES | BANK OF AMERICA, N.A. | 2013-09-26 | — | — | US | disclosed |
| WO-2011053614-A1 | CRYSTALLINE CDM-NAG AND METHODS FOR PRODUCING SAME | MERCK SHARP & DOHME CORP. (US) | 2011-05-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130253135-A1 | POLY(AMIDE) POLYMERS FOR THE DELIVERY OF OLIGONUCLEOTIDES | PUF60, POLI, PARG | MAPK1 4753/4885MEN1 3678/4885KMT2A 1244/4885 |
| US-20240018523-A1 | GALNAC COMPOSITIONS FOR IMPROVING SIRNA BIOAVAILABILITY | CSGALNACT1, B3GAT3, UGGT1 | MAPK1 4631/4885MEN1 3283/4885KMT2A 2835/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.